Home·Explore by biomarker·deficient mismatch repair (dMMR) proteins

deficient mismatch repair (dMMR) proteins

Biomarker

dMMR status reflects loss of DNA mismatch repair function. dMMR tumors are eligible for immune checkpoint inhibitor therapies.

Approvals

Indications

Therapies

Mapped tests

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where deficient mismatch repair (dMMR) proteins is defined directly in the indication labeling.

Indication	Biomarker criteria	Therapies
Colorectal Cancer (CRC) Solid Tumor · Colorectal	MLH1, PMS2, MSH2 and MSH6	OPDIVO OPDIVO + YERVOY
Endometrial Carcinoma (EC) Solid Tumor · Endometrium	MLH1, PMS2, MSH2 and MSH6	IMFINZI JEMPERLI

Tumor-agnostic approvals

Approvals defined at the solid tumor level where deficient mismatch repair (dMMR) proteins is part of the eligibility criteria.

Level	Biomarker criteria	Therapies
Solid Tumors	MLH1, PMS2, MSH2 and MSH6	KEYTRUDA JEMPERLI

Tests that measure this biomarker

These assays report deficient mismatch repair (dMMR) proteins as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test

MMR IHC Panel pharmDx

Dako Omnis

Method

IHC

Specimen

Tissue (FFPE)

Reports deficient mismatch repair (dMMR) proteins as part of its biomarker panel.

1 approvalView test profile →

Test

Ventana MMR RxDx Panel

Ventana Medical Systems, Inc.

Method

IHC

Specimen

Tissue (FFPE)

Reports deficient mismatch repair (dMMR) proteins as part of its biomarker panel.

4 approvalsView test profile →

This view is scoped to deficient mismatch repair (dMMR) proteins. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.